Hormonal
Vitamin D3 supplementation (average ~3,000 IU/day) for at least 3 months significantly reduces systolic and diastolic blood pressure, serum parathyroid hormone (PTH), high-sensitivity C-reactive protein (hs-CRP), and total cholesterol, while increasing HDL cholesterol.
If you are considering vitamin D3 for heart health, aim for a daily dose around 3,000 IU, taken consistently for at least 3 months. This approach has been shown in large-scale reviews to modestly lower blood pressure, reduce inflammation, and improve cholesterol profiles. It is not a magic bullet for arterial stiffness, but it is a low-risk strategy to support overall cardiovascular metrics, especially if you have low baseline levels.
The meta-analysis indicated a significant reduction in systolic blood pressure (SMD = −0.102 ± 0.04 mmHg...), diastolic blood pressure (SMD = −0.07 ± 0.03 mmHg...), serum PTH (SMD = −0.66 ± 0.08 ng/L...), hs-CRP (SMD = −0.20 ± 0.07 mg/L...), total cholesterol (SMD = −0.15 ± 0.06 mmol/L...), LDL (SMD = −0.10 ± 0.05 mmol/L...), triglycerides (SMD = −0.12 ± 0.06 mmol/L...) and a significant increase in HDL (SMD = 0.09 ± 0.04 mmol/L...) with vitamin D supplementation.
Why this rating
This is a systematic review and meta-analysis of 81 randomized controlled trials (RCTs) involving nearly 10,000 participants, which provides high-quality aggregate evidence, though heterogeneity exists.
Source
Vitamin D Supplementation, Serum 25(OH)D Concentrations and Cardiovascular Disease Risk Factors: A Systematic Review and Meta-Analysis
Naghmeh Mirhosseini et al. · Frontiers in Cardiovascular Medicine · 2018
DOI 10.3389/fcvm.2018.00087
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →